# NewLimit raises $435M to take cell-reprogramming into humans
> Armstrong-backed longevity firm reports age reversal in human liver cells, jumps to a $3.1B valuation and a first clinical trial

**Meta:** type: event · date: 2026-06-02 · heads: किसका पैसा, लंबी पारी · 9 takes · 3 lenses · 3 regions

## Summary

[NewLimit](/hi/entity/newlimit), the cellular-reprogramming company co-founded by Coinbase CEO Brian Armstrong and Blake Byers, closed a $435M Series C on 2 June 2026 at a ~$3.1B valuation, led by Founders Fund with Eli Lilly Ventures joining the cap table. The raise funds its first human clinical trial, after a prototype medicine reversed cell age in old human [liver cells](/hi/entity/epigenetic-reprogramming). NewLimit's approach rewrites the epigenetic markers controlling gene expression without altering the underlying DNA sequence, distinct from [gene-editing](/hi/entity/gene-therapy) cuts. The data pulled the firm's clinical timeline forward by years against its own decade-plus forecast. It is one of 2026's largest [longevity](/hi/entity/longevity) rounds, in a year on track for $8–9B in sector funding.

## By the numbers

- $435M, Series C (Founders Fund-led; closed 2 Jun 2026).
- ~$3.1B, post-money valuation.
- $110M, Armstrong's personal seed investment (2021).
- ~$3.74B, longevity-sector funding in Q1 2026 alone (49 financings).
- $8–9B, projected full-year 2026 longevity funding.

## Why it matters

Pharma money (Lilly) entering an epigenetic-reprogramming play signals the aging-biology thesis is maturing from venture science toward the clinic. Reprogramming that rejuvenates cells without cutting DNA could sidestep some gene-editing safety concerns, but human reprogramming carries its own oncogenic risks the first trial must clear.

## What to watch

- Design and IND clearance of NewLimit's first human trial.
- Whether reprogramming holds up in vivo without tumour signals.
- More pharma entrants validating (or repricing) the longevity surge.

## Regional takes (batched by bias / lens)

### unlabelled
- **STAT News** (United States, en) — Reports NewLimit's 2 Jun 2026 close of a $435M Series C to fund its first human clinical trial, after a prototype medicine reversed cell age in old human liver cells; Founders Fund led, Eli Lilly Ventures joined, at a ~$3.1B valuation.
  Source: https://www.statnews.com/2026/06/02/longevity-startup-newlimit-announces-435-million-clinical-trial-financing/
- **Crypto.news** (Global, en) — 
  Source: https://crypto.news/brian-armstrongs-newlimit-raises-435m-for-human-trials/
- **Contrary Research** (United States, en) — 
  Source: https://research.contrary.com/company/newlimit
- **Angel Investors Network** (United States, en) — 
  Source: https://angelinvestorsnetwork.com/venture-capital/newlimit-series-c-longevity-biotech-founders-fund
- **Blockonomi** (Global, en) — 
  Source: https://blockonomi.com/newlimit-series-c-armstrong-backed-longevity-startup-raises-435m/
- **Sogevity** (United States, en) — 
  Source: https://sogevity.com/newlimit-raises-435-million-cellular-reprogramming-clinical-trials-humans/
- **BioBucks (funding tracker)** (United States, en) — 
  Source: https://www.biobucks.co/biotech-vc-funding-tracker-2026

### industry
- **BioSpace** (United States, en) — Details the data behind the raise, age reversal observed in old human liver cells via epigenetic reprogramming that rewrites gene-expression markers without altering DNA, and how it pulled NewLimit's clinical timeline forward by years against its own decade-plus forecast.
  > "NewLimit snags $435M after seeing age reversal in human liver cells."
  Source: https://www.biospace.com/business/newlimit-snags-435m-after-seeing-age-reversal-in-human-liver-cells

### longevity sector
- **Longevity.Technology** (United Kingdom, en) — Sets the round in 2026's longevity surge, ~$3.74B raised across 49 financings in Q1 alone, on track for an $8–9B full year, and treats epigenetic reprogramming as the thesis pulling pharma money (Lilly) into aging biology.
  > "Longevity biotech investment 2026: we're set for a breakout year."
  Source: https://longevity.technology/news/longevity-biotech-investment-2026-were-set-for-a-breakout-year/

## Across the graph
- Related: [[retro-biosciences-valuation-2026]], [[isomorphic-labs-series-b-2026]]
- Entities: Newlimit, Longevity, Epigenetic Reprogramming, Gene Therapy, Founders Fund

---
Canonical: https://rbtfl.xyz/hi/n/newlimit-series-c-reprogramming-2026